Advaxis added to Mentor Capital Cancer Immunotherapy Index

Mentor Capital, Inc. (OTC Markets:MNTR) reports that Advaxis, Inc. (OTCBB:ADXS) has been added as the newest member of the Mentor Capital Cancer Immunotherapy Index. As with all Index companies, a portion of Advaxis shares will be purchased and included in the Mentor Capital portfolio for tracking. Cancer Immunotherapy Index creator and Mentor Capital CEO Chester Billingsley notes that only the historic Advaxis involvement in infectious disease and allergic syndromes delayed the earlier inclusion of Advaxis into Mentor's cancer-only focused Index.

“The Mentor Index has long been a prestigious cross section of the top immunotherapy companies. We at Advaxis are delighted to be part of this closely watched group of truly innovative biotech firms.”

"The beauty of the Advaxis approach is that they can tag various cancer markers like Her-2 or PSA to small, common, everyday bacteria that the human body is very used to attacking. The bacteria is weakened by a factor of 10,000 and easily defeated and engulfed. This directly introduces the attached cancer antigens inside the immune system cells. That Trojan Horse approach simultaneously activates all aspects of the immune system and points it at the cancer cells that carry the marker," explains Billingsley. Following this approach, Advaxis reports it has nine distinct cancer fighting constructs in various stages of development covering cervical, breast, head & neck, and prostate cancers.

Mentor Capital created the Cancer Immunotherapy Index in July 2009. The company and its shareholders aim to provide socially responsible funding for these and other leading edge cancer therapy and development companies. The best nonprofit and university breakthroughs must be developed and tested by these exact same firms before they can be released into medical use. Advaxis Chairman/CEO Thomas A. Moore comments, "The Mentor Index has long been a prestigious cross section of the top immunotherapy companies. We at Advaxis are delighted to be part of this closely watched group of truly innovative biotech firms."

The Mentor Capital Cancer Immunotherapy Index companies include: Dendreon (NASDAQ:DNDN), Immunocellular Therapuetics, Ltd. (OTCBB:IMUC), Oncothyreon (NASDAQ:ONTY), Agenus (NASDAQ:AGEN), Biovest International (OTC Markets:BVTI), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (OTCBB:NWBO), Provectus Pharmaceuticals, Inc. (OTCBB:PVCT), CEL - SCI Corp. (AMEX:CVM), Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly owned immunotherapeutic subsidiary, Antigen Express, and Advaxis, Inc.

The Index company summaries can be tracked through updates of the Cancer Immunotherapy Index presented at www.MentorCapital.com.